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Abstract
Distinct luteinizing hormone receptor (LHR) protein variants exist due to the posttranslational modifications. Besides
ovaries, LHR immunoreactivity (LHRI) was also found in other tissues, such as the brain, fallopian tube, endometrium,
trophoblast and resident tissue macrophages. The 3B5 mouse monoclonal antibody was raised against purified rat LHR.
In rat, porcine and human ovaries, the 3B5 identified six distinct LHR bands migrating at ~92, 80, 68, 59, 52 and 48 kDa.
Characteristic LHRI was detected in rat, human and porcine corpora lutea. During cellular differentiation, subcellular
LHR distribution changed from none to granular cytoplasmic, perinuclear, surface, nuclear and no staining. There were
also differences in vascular LHR expression – lack of LHRI in ovarian vessels and strong staining of vessels in other tissues
investigated. In normal human term placentae, villous LHRI was associated with blood sinusoids and cytotrophoblast cells,
and rarely detected in trophoblastic syncytium. In all abnormal placentae, the LHRI of sinusoids was absent, and syncytium
showed either enhanced (immature placental phenotypes) or no LHRI (aged placental phenotype). LHRI in human brain
was identified in microglial cells (CD68+ resident macrophages). Protein extracts from human vaginal wall and levator
ani muscle and fascia showed strong ~92 and 68 kDa species, and LHRI was detected in smooth muscle cells, fibroblasts,
resident macrophages and nuclei of skeletal muscle fibers. Our observations indicate that, in contrast to the theory on
the role of vascular hormone receptors in preferential pick up of circulating hormones, there is no need to enhance
selective pick up rather only prevent LH/CG transport to inappropriate sites. Abnormal placental LHR expression may
play a role in the development of abnormal pregnancy. Expression of LHR in the pelvic floor compartments suggests that
high LH levels in postmenopausal women may contribute to the pelvic floor relaxation and increased incidence of pelvic
floor disorders. Since chorionic gonadotropin increases secretion of a variety of cytokines by monocytes, and induces
their inflammatory reaction and phagocytic activity, high LH levels in aging individuals may also activate microglia
(mononuclear phagocyte system in the central nervous system) and contribute to the development of Alzheimer's
disease and other inflammation-mediated neurodegenerative diseases.
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Background
The luteinizing hormone receptor (LHR) plays a funda-
mental role in ovarian responsiveness to pituitary LH. The
LHR consists of a 335 residue extracellular domain which
contains six N-linked glycosylation sites [1]. Posttransla-
tional changes in glycosylation and phosphorylation
result in several LHR variants migrating between ~93 and
44 kDa [2–17]. Lower molecular weight forms (48 and 44
kDa species) appear to represent a glycosylated extracellu-
lar domain expressed in mammalian cells (truncated
receptor) and retain hormone binding specificity. They
are not secreted from cells, but remain trapped intracellu-
larly [18]. In addition to various glycosylated LHR vari-
ants, western blotting also yielded a 170 kDa band
representing an LHR dimer [19]. LH binds to LHR variants
with different affinities, and highest affinity appears to be
associated with the fully glycosylated receptor (~90 kDa)
[19]. Chorionic gonadotropin (CG), which is important
for corpus luteum (CL) rescue and maintenance of preg-
nancy, also binds to LHR, although with a 10-fold lower
binding affinity compared with that of LH [20].
The mouse anti-rat LHR monoclonal antibody (mAb),
clone 3B5, was developed against purified rat LHR [21].
The antibody showed immunoreactivity with rat granu-
losa cells of mature (preovulatory) follicles, ovarian thecal
and interstitial cells, granulosa-lutein cells of developing,
mature and regressing CL, and with testicular Leydig cells,
and no reactivity with rat kidneys [22]. During the last ten
years, affinity purified 3B5 antibody has been used in sev-
eral immunohistochemical studies [23–26]. To our
knowledge, however, no analysis of the 3B5 antibody by
western blot has been reported.
In porcine ovaries, LHR expression was detected in granu-
losa and theca cells of preovulatory follicles, but not in
granulosa lutein cells of the mature CL [27]. In human
ovaries, LHR expression was also detected in granulosa
and theca cells of preovulatory follicles, but mature CL
showed strong expression in luteal cells, which disap-
peared during luteal regression. CL from early human
pregnancies showed various intensities of LHR expression
(from weak to intense) on the surface and in the cytoplas-
mic regions of luteal cells [24].
LHR expression was also detected in nonpregnant human
uterus (glandular and luminal epithelial cells, stromal
cells, myometrial cells and vascular smooth muscle cells),
syncytiotrophoblast of midterm but not term human pla-
centa, fetal membranes and decidua [28], human and rat
brain [29,30], rat prostate [14,15], human trophoblast
and syncytiotrophoblast from early pregnancies [31], por-
cine fallopian tubes and umbilical cord [16,32], ovarian,
decidual, endometrial and luteal macrophages [22,33],
and ovarian cancer cell cultures and tumor tissues [34].
Beside its involvement in the regulation of ovarian func-
tion, the LHR appears to be involved in some additional
effects. LHR immunoreactivity in porcine fallopian tubes
was confined to the epithelium and smooth muscle cells,
and in vitro LH treatment caused relaxation of the oviduct
[35]. Also, LHR stimulation plays a role in the induction
and maintenance of myometrial quiescence [36–38].
Since smooth muscles belong among important compart-
ments of the pelvic floor, high LH levels after menopause
might be involved in the increased incidence of pelvic
floor disorders, a common condition in postmenopausal
women [39]. Since the brain was reported to express func-
tional LHR [29,30], there is also a possibility that high LH
levels in aging individuals may in some way participate in
the development and progression of neurodegenerative
process of several degenerative neurological diseases,
including Alzheimer's disease.
The aim of the present study was to investigate subcellular
LHR distribution and determine LHR protein variants
identified by 3B5 mAb in various rat, human and porcine
tissues. During cellular differentiation, a transition from
cytoplasmic to perinuclear, surface, nuclear and no LHR
immunoreactivity was detected. In protein extracts from
rat, porcine and human ovaries six distinct LHR bands
were observed, migrating between ~92 and 48 kDa.
Materials and Methods
Rats
Rats of the CII-ZV strain, born and maintained in the Lab-
oratory of Biology of Reproduction, Zaragoza, Mexico,
were maintained on a 14L-10D cycle (lights on 0500–
1900 h). The postnatal rats were weaned at 21 days of age,
and they attained sexual maturity during the 6th week of
life. Ovaries were studied in proestrous rats, at the age of
two months. Daily vaginal smears were collected for
about ten days prior to sacrifice.
Porcine tissues
Twenty porcine ovaries with fallopian tubes and some
additional porcine tissues were obtained from a local
abattoir and tissue samples were frozen within one hour.
With respect to the follicular and luteal development, por-
cine ovaries were macroscopically classified as follows:
Early/mid follicular – medium sized antral follicles (3–5
mm) accompanied by shrinking fibrous corpora lutea of
similar size; late follicular – large antral follicles (>5 mm)
not accompanied by any luteal tissue; early/ mid luteal –
large corpora lutea (~10 mm) characterized by yellowish
color; and late luteal – CL of diminishing size (~7 mm)
with massive bleeding into the central cavity (bluish
color) and no accompanying follicles.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/46
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Human tissues
Frozen blocks of human tissues from previous studies
were obtained as described previously [40–44]. Some tis-
sues also originated from the Cooperative Human Tissue
Network, Columbus, Ohio. Functional stage of ovaries
was classified according to the endometrial morphology
[45]. Ovaries and endometrial samples were obtained
from hysterectomy specimens. We also utilized frozen
blocks and protein extracts from human placental chori-
onic villi, and protein extracts from trophoblast cultures
and cultured amniotic fibroblasts and placental mononu-
clear cells [46]. Placental mononuclear cells were col-
lected from the first digestion, which contains no
trophoblast cells [46]. The study was approved by the
Institutional Animal Care and Use Committee and Insti-
tutional Review Board.
Tissue processing and peroxidase immunohistochemistry
All chemicals, except where specified otherwise, were pur-
chased from Sigma Chemical Co., St. Louis, MO. Tissue
samples were collected into cryomold biopsy vinyl speci-
men molds (Tissue-Tek Cryomold Biopsy, Miles Inc.
Diagnostic Division, Elkhart, IN) and embedded in an
optimum cutting temperature formulation of water-solu-
ble glycols and resins (O.C.T. compound; Miles). The
molds with specimens were frozen by floating on liquid
nitrogen and stored at -80°C until use. Frozen tissues were
sliced into 7 µm serial sections using a cryostat microtome
with specimen retraction during return travel (Carl Zeiss
Microm HM 505 E; MICROM Laborgeräte GmbH, Wal-
dorf, Germany) and ten to twelve distinct tissue sections
were placed on each slide. The slides were dried ~2 h at
room temperature, fixed 5 min in acetone, dried 30 min,
and stored at -80°C until immunoperoxidase staining was
performed. Prior to staining, to prevent water condensa-
tion, the slides were transferred at -80°C into pre-chilled
air protected boxes containing Drierite granules (W.A.
Hammond Drierite Co, Ltd, Xenia, OH), and the boxes
with slides were equilibrated to -20°C, +4 (cold room)
and room temperature (20 min each step) before
opening.
Slides were incubated overnight (cold room) with pri-
mary antibodies (see below). Specimens were then trans-
ferred to room temperature, extensively washed in freshly
prepared PBS, pH 7.22, and incubated 20 minutes with
swine anti-mouse IgG peroxidase conjugate (SwAM;
SEVAC Praha, Prague, Czech Republic) diluted 1:20, and
preabsorbed with rat kidney homogenate to remove non-
specific background [46]. Control slides were similarly
processed, but primary antibody was replaced with PBS.
Antigen-antibody complexes were detected by standard
diaminobenzidine technique (brown color). Some slides
were counterstained with hematoxylin, and all slides were
dehydrated and mounted. Dual color immunohistochem-
istry experiments were performed as described previously
[47].
Evaluation was performed on a Leitz DM RB (Leica Inc.,
Wetzlar, Germany) microscope equipped with differential
interference contrast and a DEI-470 CCD Video Camera
System (Optronics Engineering, Goleta, CA) with detail
enhancement. The video images were captured by CG-7
color frame grabber (Scion Corporation, Frederick, MD)
supported by Scion Image public software developed at
the National Institutes of Health (Wayne Rasband, NIH,
Bethesda, MD), and ported into Microsoft® Power-Point®
97 SR-2 (Microsoft Corporation, Redmont, WA).
Primary antibodies
For LHR immunohistochemistry, the 3B5 affinity purified
antibody was used at 50 µg/ml. The antibody is IgG1 class,
developed and characterized previously [21,22]. The anti-
body was stored at -80°C, either as a lyophylizate, or in
diluted aliquots. For immunoblots, the antibody concen-
tration was 10 µg/ml. We also used mouse anti-human
Thy-1 mAb, clone F15-42-01 [48] (Dr. Rosemarie Dal-
chau, Institute of Child Health, London, UK), a marker of
placental decidual cells (and fibroblasts and brain tissue)
[46], mouse anti-rat Thy-1, clone OX-7 [49] (Dr Alan F.
Williams, University of Oxford, Oxford, UK), mAbs
against CD68, a marker of tissue macrophages, and CD14,
a marker of monocytes (Dako Corporation, Carpinteria,
CA), and leukocyte-common antigen, clone F10-89-4 [50]
(Dr. John F. Fabre, Institute of Child Health, London,
UK).
Tissue extracts and western blot analysis
For preparation of protein extracts from rat, human and
porcine tissues for western blot analysis, 150 cryostat
tissue sections (7 µm) were collected into microcentrifuge
tubes and lysed by adding ice-cold lysis buffer (20 mM
Tris pH 7.5, 200 mM NaCl, 0.25% Nonidet P-40; 400 µl/
100 mg of tissue sections) containing 1 mM sodium
orthovanadate, 10 mM sodium fluoride, and 1 mM phe-
nylmethylsulfonyl fluoride. Tissue culture cells were col-
lected and processed as described previously [46].
After 15 min on ice, the tissue and cell lysates were soni-
cated using a SonicatorTM Cell Disruptor (Heat Systems-
Ultrasonic, Inc., Plainview, NY) for 5 seconds, and centri-
fuged at 11000 × g for 20 min at 4°C. Supernatants were
stored at -80°C. For western blot analysis, protein concen-
trations were determined by Bradford assay (Bio-Rad,
Hercules, CA). Equal amounts of unboiled protein (60
µg) were loaded onto reducing 10% SDS-Tris-glycine
polyacrylamide gels, transferred to nitrocellulose (Bio-
Rad), and processed as described previously [51], with
some modifications.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/46
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Briefly, membranes were washed in Tris-buffered saline
containing 0.05% Tween 20 (TBST) and non-specific
binding sites were blocked by immersing the membrane
in blocking reagent (0.5% casein in TBST) for 1 hour at
room temperature on an orbital shaker. After blocking,
the membranes were briefly rinsed in two changes of
TBST, and washed once for 15 minutes and twice for 5
minutes in fresh changes of TBST. The membranes were
subjected to overnight incubation (4°C) with mouse anti-
rat LHR monoclonal antibody in blocking reagent.
The membranes were washed and incubated with peroxi-
dase labeled secondary antibody – goat anti-mouse IgG
and IgM (Jackson Immunoresearch, West Grove, PA)
diluted 1:2000 – for 1 hour at room temperature. Before
staining, the secondary antibody was diluted 1:60 (5 µl/
300 µl), absorbed with rat kidney homogenate (150 mg/
300 µl) for 20 min, centrifuged and diluted 1:2000 to the
final concentration. This absorption eliminated any non-
specific background. After incubation, the membranes
were washed 1 × 15 min, 2 × 10 min and 4 × 5 min in fresh
changes of TBST, and incubated for 1 hour in blocking
buffer at room temperature. Bound antibodies were
detected by a chemiluminescent detection system (ECL;
Amersham Pharmacia Biotech, Piscataway, NJ) as recom-
mended by the manufacturer's protocol. For exposure (1
min, 5 min, and up to 1 h) we used Kodak XAR film (East-
man Kodak, Rochester, NY).
For protein load control, the membranes were reprobed
with actin mouse mAb, clone C4 (Boehringer Mannheim
Corp., Indianapolis, IN) at 0.25 µg/ml, and developed as
above.
Absorption studies
We also included absorption studies with porcine ovarian
homogenates. Primary antibody (100 µg) in 2 ml PBS was
incubated 20 min with 500 mg of porcine ovarian
homogenate (late follicular phase) at room temperature.
After centrifugation (11000 × g for 10 min at 4°C), the
supernatant was diluted to 10 ml with blocking reagent
and used for immunostaining of nitrocellulose
membranes.
Results
Rat tissues (Figure 1)
In rat ovaries, the LHR immunoreactivity was detected in
the mature and regressing CL (MCL and RCL, Fig. 1A) and
ovarian interstitial cells (i), follicular theca interna (t, Fig.
1B), and mature granulosa cells (mg, Fig. 1B vs. control,
1C). Note a lack of immunoreactivity in ovarian vessels
(v, Fig. 1A). The antibody also identified granular cyto-
plasmic LHR immunoreactivity in immature granulosa
cells (ig, Fig. 1B) of preantral and early antral follicles,
suggestive of early LHR synthesis. This may represent syn-
thesis of a receptor extracellular domain not yet associated
with the cell surface, but remaining trapped intracellularly
[18].
Maturation of preovulatory follicles was associated with a
transition of scarce granular cytoplasmic LHR immunore-
activity (ig, Fig. 1D) to LHR accumulation in more differ-
entiated granulosa cells (dg). LHR immunoreactivity was
also found in surface epithelium of the rat uterine cavity,
epithelium of uterine glands (se and ug, Fig. 1E), nuclei of
stromal cells (arrowhead), and in uterine vessels (v). The
latter contrasted with a lack of staining of ovarian vessels
(see above).
Human tissues (Figure 2)
During follicular selection (mid follicular phase, as deter-
mined by endometrium morphology) dominant follicles
in human ovaries showed granular cytoplasmic LHR
expression in granulosa cells (g, Fig. 2A), similar to those
in immature rat follicles (see above). Theca interna (ti)
showed more distinct LHR immunoreactivity, character-
ized by accumulation of LHR cytoplasmic granules. Follic-
ular vessels (vascular layer, vl, and thecal vessels, tv) were
virtually unstained. Some LHR immunoreactivity was also
detected in theca externa cells (te).
Early luteal development (fresh CL) was associated with
very strong cytoplasmic LHR immunostaining of granu-
losa lutein cells migrating into the follicular cavity (gl, Fig.
2B). Adjacent theca-lutein cells (tl) also exhibited promi-
nent staining, but showed distinct vacuolization. No LHR
expression accompanied developing luteal vessels (v). In
the mature CL, granulosa lutein cells showed diminution
of cytoplasmic LHR immunoreactivity and strong surface
staining (Fig. 2C). Luteal cells in the old CL (late luteal
period) showed marked diminution of LHR expression
(Fig. 2D). Regression of luteal tissue (CL investigated dur-
ing the follicular phase) showed residual staining of
theca-lutein cells and no staining of regressing granulosa
lutein cells (Fig. 2E vs. ctr).
In CL of pregnancy (CLP; 3 months), less or more distinct
granular cytoplasmic LHR immunoreactivity (arrowhead,
Fig. 2F vs. ctr) and no surface staining was detected. This
suggests that high CG levels accompanying early preg-
nancy may preserve CLP through the cytoplasmic recep-
tor. In other words, selective pick up of CG through the
surface LHR expression in granulosa lutein cells during
the luteal phase after conception appears not to be
required if the circulating CG is very high.
In fallopian tubes, distinct cytoplasmic LHR expression
was associated with the luminal aspect of epithelial cells
(arrowhead, Fig. 2G). In endometrium (late follicular
phase – note stromal edema), LHR immunoreactivity wasReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/46
Page 5 of 18
(page number not for citation purposes)
associated with endometrial glands (g, Fig. 2H) and with
the surface epithelium of the uterine cavity (se). There was
also granular cytoplasmic expression in endometrial stro-
mal cells (s), precursors of decidual cells, and similar
granular staining was observed in smooth muscle cells of
late follicular phase myometrium (data not shown). 3B5
antibody also stained human brain vessels (v, Fig. 2I) and
showed strong LHR immunoreactivity with microglial
cells (arrowhead; see Fig. 8).
Porcine tissues (Figure 3)
Porcine preovulatory follicles showed distinct LHR stain-
ing of theca interna, lack of LHR expression in vascular
layer under the follicular membrane, and transition of
granular cytoplasmic to surface LHR immunoreactivity in
granulosa cells (Fig. 3A,3B,3C, vs. control D). Mature CL
showed strong surface LHR immunoreactivity of luteal
cells (Fig. 7E), and old corpora lutea showed diminution
of LHR immunoexpression (Fig. 3F). Ovarian surface epi-
thelium, the source of most ovarian tumors, was also
Figure 1
LHR expression in the rat ovaries and uterus. A) Strong LHR immunoreactivity is apparent in mature (MCL) and regressing CL 
(RCL) and interstitial cells (i). Note unstained vessels (v). B) Strong staining of theca interna (t) and weaker staining of mature 
granulosa cells (mg) in preovulatory follicle. Note scarce cytoplasmic granules with LHR immunoreactivity in immature granu-
losa cells (ig). C) Control. D) Increased staining during granulosa cell differentiation (dg) in large antral follicle. E) In the rat 
uterus, the LHR immunostaining is apparent in the surface epithelium (se), uterine glands (ug) and vasculature (v). Uterine stro-
mal cells show nuclear staining (arrowhead). No hematoxylin counterstain.
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Figure 2
Reactivity of 3B5 with human tissues. A) Dominant follicle (DOF, midfollicular phase) – g, granulosa; vl, vascular layer; ti, theca 
interna; tv, thecal vessels; te, theca externa. B) Fresh CL – gl, granulosa lutein cells; tl, theca lutein cells; v, proliferating luteal 
vessels. C) Mature CL – midluteal phase. D) Old CL (OCL, late luteal phase). E) Regressing CL (RCL, mid-follicular phase of 
the subsequent cycle). F) Corpus luteum of pregnancy (CLP, 3rd month of pregnancy) Arrowhead indicates cytoplasmic LHR 
immunoreactivity. G) Fallopian tube. Arrowhead indicates LHR immunoreactivity at the luminal aspects of epithelial cells. H) 
Endometrium (EM, late follicular phase – note stromal edema) – se, surface epithelium; g, glands; s, endometrial stromal cells. I) 
Staining of brain microvasculature (v) and microglial cells (arrowhead – see Fig. 8). Insets show control staining (ctr). Hematox-
ylin counterstain except panel F.
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Figure 3
LHR immunostaining in porcine tissues. A–C) Preovulatory follicles (late follicular phase) show a transition from granular cyto-
plasmic to surface LHR immunoreactivity in granulosa cells (arrowheads), lack of staining of vascular layer, increase of LHR 
staining in theca interna and extreme dilatation of follicular microvasculature (v). D) Control for C. E) Mature CL. F) Old CL. 
G) Ovarian surface epithelium (arrowhead). H) Fallopian tube (FT). I) Skin vessels show strong LHR immunoreactivity of the 
entire vascular wall (arrowhead). J) In ovarian vasculature, the LHR immunoreactivity is limited to the nuclei of some endothe-
lial cells (arrowhead) but other components of vascular wall are unstained. Insets in E–J show control staining. Details in text. 
Hematoxylin counterstain except panels A–D, H and I.
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stained (arrowhead, Fig. 3G). In porcine fallopian tube
(Fig. 3H), the LHR immunostaining was similar to that in
human oviduct. Strong LHR immunoreactivity in vascular
walls was detected in the skin (Fig. 3I), which does not
represent a classic LH/CG target. This contrasted with a
lack of staining in ovarian vessels, except weak nuclear
staining of endothelial cells (arrowhead, Fig. 3J). Insets in
Fig. 7E,7F,7G,7H,7I,7J show the control procedure.
Observations of LHR immunoreactivity in porcine tissues
indicate that LHR distribution is similar to that in human
tissues. They also show LHR expression in the ovarian sur-
face epithelium (not investigated in human ovaries) and
astonishing differences in vascular walls of nonclassic
(strong LHR in skin vessels) and classic LHR targets (week
expression in ovarian vessels) – see Ref. [40] and Discus-
sion beneath for a role of vascular LHR expression in the
LH/CG delivery.
Multiple rat, human and porcine LHR protein variants 
(Figures 4 and 5)
Western blot analysis of protein extracts from normal rat
ovaries and human and porcine mature CL with 3B5 anti-
body showed six distinct bands migrating between ~92
and ~48 kDa (lanes 2, 4 and 6, Fig. 4; see also Fig. 5A).
Although weak, some LHR immunoreactivity was also
detected in the rat kidney protein extract (lane 1). This
observation is consistent with a lack of LHR immunoreac-
tivity in rat kidney cryostat sections reported previously
[22].
Distinct LHR expression was detected in rat proestrous
ovaries (lane 2, Fig. 4), which contain LHR+ CL at various
stages of development and regression, and developing
and mature preovulatory follicles. However, in porcine
preovulatory ovaries (late follicular phase), which contain
numerous preovulatory follicles but no luteal tissue, very
strong LHR immunoreactivity was also detected (lane 3,
Fig. 4). Regression of porcine luteal tissue (RCL; lane 5)
was associated with a marked decline of LHR expression.
This confirmed immunohistochemical observations.
In human tissues, mature CL (MCL; lane 6) showed LHR
bands similar to that in mature porcine CL. Very strong
expression of all six LHR variants was detected in the fal-
lopian tube (FT; lane 7), which is the site of first contact
with the developing embryo secreting CG, a signal
required for CL preservation.
Figure 4
Western blot analysis of rat, porcine and human tissues with 3B5. KN, kidney; Ov/P, ovary in proestrus; POF, preovulatory fol-
licle; MCL, mature CL; RCL, regressing CL (follicular phase); FT, fallopian tube; CV, chorionic villi (term placenta); T:0, time 0 
trophoblast culture; EC, early culture (24 h); LC, late culture (72 h); MC, cultured placental mesenchymal cells; FB, cultured 
amniotic fibroblasts; VagW, vaginal wall (epithelium, connective tissue and smooth muscle bundles); LM, levator ani muscle; LF, 
levator ani fascia. Details in text.
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Placental chorionic villi (CV; lane 8) also showed six dis-
tinct bands similar to those detected in the rat, human
and porcine ovaries. However, time 0 and early and late
trophoblast cultures derived from the same placenta
(lanes 9–11) showed additional high molecular weight
LHR variants (~170 kDa), possibly LHR homodimers
[19], which were barely detectable or undetectable in
other tissues, including placental CV. Moreover, there
Figure 5
3B5 absorbed with porcine ovaries (western blot control). Reactivity of 3B5 in western blots (A) diminishes after preabsorp-
tion with porcine ovaries [porcine ovary absorbed (POA) 3B5] (B). C) Actin control for protein loading. For abbreviations see 
Fig. 4.
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were additional bands detected in trophoblast cultures
(~85, 60, and 46 kDa species) and a lack of a ~52 kDa var-
iant as compared to the luteal, FT and CV protein extracts.
The 44 kDa species, probably a partially degraded form
from LHR turnover [18], was observed in placental
cultures (lanes 9–13) and pelvic floor compartments
(lanes 14–16).
We also investigated cultures of placental mesenchymal
cells (MC), which are always associated with trophoblast
cultures [40,41], and amniotic fibroblasts (FB). Placental
mesenchymal cells showed a prominent LHR band at ~68
kDa (lane 12). Note the virtual lack of other bands char-
acteristic of trophoblast cultures. Placental amniotic
fibroblasts showed two distinct LHR bands migrating at
~59 and 48 kDa (lane 13). Similar ~59 and 48 kDa species
were distinctly expressed in trophoblast cultures.
Western blot analysis of pelvic floor compartments
showed strong expression of ~92 and 68 kDa species in
protein extracts from the vaginal wall (VagW; lane 14),
which consists of vaginal epithelium, longitudinal and
circular smooth muscle cell bundles, and connective tis-
sue. A less prominent band was detected at ~80 kDa.
Three similar bands were also found in human levator ani
muscle and fascia (lanes 15 and 16). These observations
indicate that pelvic floor compartments represent poten-
tial targets for the LH/CG effect. Absorption with porcine
ovaries resulted in severe diminution of 3B5 reactivity
with rat, porcine and human tissues in western blots (Fig.
5B vs. 5A).
Altogether, these data indicate that the 3B5 antibody iden-
tifies six LHR protein variants showing distinct expression
in rat, porcine and human tissues, including human pla-
centa, with some variants also detected in human female
pelvic floor compartments.
Human chorionic villi and placental membranes (Figure 6)
In normal placentae at term, the LHR immunoreactivity in
mature chorionic villi was found in mononucleated
cytotrophoblast cells under the syncytial layer (arrow-
heads, Fig 6A) and villous vascular sinusoids (v), but most
of the syncytiotrophoblast was virtually unstained (white
asterisks vs. black). Mononucleated trophoblast cells
showed variable nuclear LHR immunoreactivity (Fig. 6B,
detail from A). The most prominent nuclear staining was
found in trophoblast cells merging with the syncytium
(full arrowheads vs. white). The red arrowhead indicates
diminution of LHR expression in the cell which joined the
syncytial layer. Staining of villous sinusoids was associ-
ated with basal (abluminal) aspects of endothelial cells
(arrowheads, Fig. 6C). Developing (immature) chorionic
villi were occasionally observed and showed more pro-
nounced granular cytoplasmic LHR immunoreactivity in
the syncytial layer (asterisk, Fig. 6D), a feature also
detected in immature granulosa cells (see above).
In contrast to normal placentae, granular cytoplasmic
staining of the syncytial layer dominated in some moder-
ately abnormal placentae (asterisks, Fig. 6E), which
showed mild compensatory dilatation of villous sinu-
soids (v) – see Ref. [52] for definition of placental abnor-
mality. In such placentae, the LHR+ mononucleated
trophoblast cells were barely detectable, as well as LHR
expression in villous sinusoids (white arrowheads).
Differences between placental types were more obvious at
lower magnification. Figure 6F (vs. control 6I), shows nor-
mal placenta with prominent LHR staining of villous
sinusoids (full arrowhead) and no staining of syncytium
(white asterisk). Figure 6G shows LHR immunostaining
of syncytium (black asterisk) and lack of vascular LHR
(white arrowhead), resembling immature chorionic villi
(immature placental phenotypes, characteristic for intrau-
terine growth retardation and maternal diabetes [52] –
note lack of dilatation of villous sinusoids). Figure 6H
shows that neither surface (white asterisk) nor significant
vascular LHR immunoreactivity (white arrowhead) was
detected in placentae with extreme dilatation of villous
sinusoids (aged placental phenotype [52]).
In placental membranes, occasionally found multilayered
amniotic epithelium showed no or fine granular cytoplas-
mic staining of epithelial cells adjacent to the basement
membrane (full arrowhead, Fig. 6J), followed by
perinuclear (yellow arrowhead) and nuclear LHR immu-
noexpression (red arrowhead). Cells most distant from
the basement membrane showed no staining (white
arrowhead).
Extravillous trophoblast cells in placental membranes and
placental basal plate (Fig. 6K) exhibited usually perinu-
clear (full arrowheads) and occasionally nuclear LHR
expression (data not shown). In contrast, however,
nuclear or no staining was prevalent in adjacent decidual
cells (white arrowheads). Fig. 6L shows a semi-parallel
section stained for Thy-1 glycoprotein, a characteristic
marker of human decidual cells [46]. Note Thy-1+ decid-
ual cells (white arrowhead) and unstained extravillous
trophoblast cells (full arrowhead). Dual color immuno-
histochemistry for LHR (brown) and CD68 (blue; Fig.
6M) indicates that LHR+ decidual cells also show expres-
sion of CD68 (white arrowhead – note brown and blue
color) of decidual macrophages (red arrowhead), i.e.,
marker also characteristic for regressing luteal cells [40].
Note a lack of macrophages among trophoblast cells.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/46
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Figure 6
LHR immunoreactivity in chorionic villi and placental membranes. A) LHR+ mononucleated trophoblast (arrowheads) and vil-
lous vascular sinusoids (v) in normal term placentae. Note unstained syncytium (white asterisks) or sporadic LHR+ granules 
(black asterisk). B) Detail from (A) (turned 90°) shows cytotrophoblast cells merging with syncytium (full arrowheads vs. white 
arrowhead), followed by diminution of LHR immunoreactivity (red arrowhead). C) Villous sinusoids. D) Immature (developing) 
villus in normal placenta. E) Abnormal placenta (note enhanced dilatation of all sinusoids – compare with A). Panels (F–H) 
show staining for LHR (DAB-Ni substrate) in various placental types (see text) vs. control (I). J) Occasionally detected multi-
layered amniotic epithelium shows a transition from granular cytoplasmic (full arrowhead) to perinuclear (yellow arrowhead) 
and nuclear LHR immunoreactivity (red arrowhead). Note unstained surface cells (white arrowhead). K) Extravillous trophob-
last cells (basal plate) with strong perinuclear staining (full arrowheads) variable LHR immunoreactivity in decidual cells (white 
arrowheads). L) Parallel section shows Thy-1+ decidual cells (white arrowhead) and unstained trophoblast cells (full arrow-
head). M) Dual color immunohistochemistry: extravillous trophoblast expressing LHR (full arrowhead), decidual cells express-
ing both markers (white arrowhead) and decidual macrophages expressing CD68 only (red arrowhead). Hematoxylin 
counterstain except panels F–I and panel M (dual color immunohistochemistry). Bar in C, for B and C; bar in H, for F–I. For 
other panels see bar in A.
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Figure 7
LHR immunoreactivity and resident macrophages in the female pelvic floor. A) Vaginal smooth muscle (Vag SM): cytoplasmic 
(full arrowhead) and nuclear LHR immunoreactivity (white arrowhead). B) Vaginal connective tissue (Vag ct): fibroblast type 
cells (white arrowhead), rounded mesenchymal cells (full arrowhead) and vessels (red arrowhead). C) Vaginal epithelium (Vag 
Ep): basal (stem) cells (b), parabasal cells (full arrowhead) and intermediate cells (yellow and green arrowheads). Superficial 
layer (middle inset): nuclear staining (red arrowhead) and diminution of staining in the surface cells (white arrowhead). D) 
Levator ani fascia (LF): principal cells (fibroblasts; white arrowhead) and rounded mesenchymal cells (full arrowhead). E) Leva-
tor ani muscle (see also F for detail): mesenchymal cells among muscle fibers (full arrowhead) and muscle cell nuclei (white 
arrowheads). CD68 staining in vaginal connective tissue (G), levator fascia (H) and levator muscle (I). Insets indicated as ctr 
show control staining. No hematoxylin counterstain except panels G–I. Bar in I for all panels except E.Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/46
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Figure 8
LHR immunostaining in the gray matter of the human brain parietal lobe. A) LHR+ microglial cells with characteristic dendritic 
processes (full arrowhead) and flattened nuclei (yellow arrowheads). Green arrowhead indicates unstained nerve cell. B) Area 
occupied by microglia (full and yellow arrowheads) contains unstained nerve cells (green arrowheads). However, area lacking 
microglia contains LHR+ nerve cells (red arrowheads). C) Staining for leukocyte common antigen (LCA) reveals picture similar 
to that in (A). Note dendritic processes of microglial cells (full arrowheads), and interaction with neuronal (red arrowhead) 
and other glial elements (white arrowhead). D) Anti human Thy-1 (hThy-1) shows diffuse staining of brain tissue except for the 
vascular endothelium (v). E) Control staining with anti-rat Thy-1 (rThy-1). F–K) Schematic drawings of interstitial (glial) cells in 
the human brain and differences in their nuclei (from Ref. [54]). F) Fibrous astrocytes – white matter. G) Oligodendroglial cells 
– satellites to nerve cells. H) Protoplasmic astrocytes – grey matter. I) Microglial cells – mesodermal origin, gray and white 
matter. Yellow arrowhead indicates flattened nucleus of microglial cell. J) Irregularly oval nuclei of astrocytes (full arrowhead) 
and oval nuclei of oligodendroglia (white arrowhead). K) Small, often flattened nuclei of microglial cells. L) CD68 staining 
shows flattened nucleus of microglial cell (yellow arrowhead). M) No staining was observed with CD14, a marker of mono-
cytes and immature tissue macrophages. Hematoxylin counterstain: weak in panels A and B, moderate in C-E, L and M. Bar in 
M, for A-E, L and M.
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Pelvic floor (Figure 7)
Previously documented LH-dependent relaxation of the
porcine oviduct [53] raises a question if high LH levels in
postmenopausal women do not contribute to the relaxa-
tion of the pelvic floor, and hence to the increased inci-
dence of pelvic floor disorders in these females. We
investigated connective tissues and muscular compart-
ments of the pelvic floor, in order to determine cellular
equivalents to LHR bands detected in western blots and
possible cellular targets for the LH effect.
Strong cytoplasmic and nuclear LHR immunoreactivity
was found in smooth muscle cells in the vaginal wall (Fig.
7A vs. ctr). Vaginal connective tissue fibroblasts (white
arrowhead, Fig. 7B) and other stromal elements (full
arrowhead), as well as vaginal vessels (red arrowhead),
also showed distinct LHR immunoreactivity.
In vaginal epithelial layers, a model for differentiation of
epithelial cells [42], basal (stem) cells were unstained (b,
Fig. 7C), dense cytoplasmic staining was found in paraba-
sal (immature) cells (full arrowhead), followed by perinu-
clear (yellow arrowhead) and cell surface LHR
immunoreactivity (green arrowhead). Nuclear staining
was found in lower superficial cells (red arrowhead in
adjacent panel), and cornified superficial cells showed
overall diminution of LHR immunoreactivity (white
arrowhead).
Additional pelvic floor structure, the levator ani fascia,
was studied and exhibited nuclear LHR immunoreactivity
in principal cells (fibroblasts; white arrowhead, Fig. 7D)
and other mesenchymal cells with rounded nuclei (full
arrowhead), most probably resident macrophages (see
below). Mesenchymal cells in levator ani muscle also
showed LHR immunoreactivity (full arrowheads, Fig. 7E
and 7F). In addition, nuclear LHR staining was also
detected in levator ani striated muscle fibers, some of
which were centrally (abnormally) located in this sample
(white arrowheads, Fig. 7E and 7F). Note unstained mus-
cle vessels (v) accompanied by LHR+ stromal cells.
Distribution of resident macrophages, as shown in Fig.
7G,7H,7I, suggests that rounded mesenchymal cells
showing LHR immunoreactivity in pelvic floor connective
tissues might be represented by this type of cells. Note
association of some resident macrophages with vascula-
ture (v).
These observations indicate that principal components of
the pelvic floor (smooth muscle cells, fibroblasts and stri-
ated muscle fibers), which are responsible for pelvic floor
integrity, are potential targets for LH/CG hormonal
effects. Additional cells exhibiting LHR immunoreactivity
in pelvic floor connective tissues appear to be resident
macrophages.
Human brain (Figure 8)
Neurodegenerative diseases, including Alzheimer's dis-
ease, also show increased incidence in aging individuals.
Therefore, a question arises if the rise in LH, reflecting
diminution of sex steroids, can also contribute to the
initiation and progression of neurodegeneration. We
studied LHR expression in the gray matter of the human
parietal lobe cortex. Strong LHR immunoreactivity was
associated with small cells with flattened nuclei (yellow
arrowheads, Fig. 8A) and numerous spiny processes (full
arrowhead). Adjacent nerve cells were unstained (green
arrowheads, Fig. 8B), but distant nerve cells showed mod-
erate staining (red arrowheads).
Staining for the leukocyte common antigen (Fig. 8C) and
observation for characteristic morphology and nuclear
shape (Fig. 8I vs. 8F,8G,8H; Fig. 8K vs. 8J – adapted from
Ref. [54]) as well as expression of CD68 of resident mac-
rophages (Fig. 8L) indicate that LHR immunoreactivity in
Fig. 8A identifies microglial cells of mesenchymal (meso-
dermal) origin. Yet, Fig. 8M indicates that these cells do
not express CD14 of monocytes (and primitive tissue
macrophages [42]). This suggests that they are highly dif-
ferentiated dendritic type cells. Figure 8D shows diffuse
expression of Thy-1 in the cortex, identified with anti-
human Thy-1 antibody. Figure 8E is a control using the
anti-rat Thy-1 antibody (not reacting with human tissues).
These data indicate that microglial cells and some nerve
cells in the gray matter of the human brain cortex may be
influenced by LH/CG proteohormones. Yet, loss of gray
matter from areas of the parietal and temporal lobes is the
most obvious consequence of Alzheimer's disease
[55,56].
Discussion
Our observations indicate that the 3B5 anti-LHR antibody
reacts with rat, porcine and human tissues. In western
blots, the 3B5 antibody identifies six distinct bands
migrating between ~92 and 48 kDa, and this reactivity
with protein extracts from all three species diminishes
when the antibody is preabsorbed with porcine ovaries.
We also show changes in subcellular LHR distribution
during differentiation of various cell types. To our knowl-
edge, LHR expression in fibroblasts, striated muscle cells,
and microglial cells (CD68+ resident macrophages) in the
central nervous system is presented for the first time. We
also report tissue differences in vascular LHR expression.
During cellular differentiation, subcellular LHR distribu-
tion changed from granular cytoplasmic to perinuclear,
surface and nuclear staining; virtually no staining wasReproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/46
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detected in stem cells and most differentiated and aged
cells. Yet, cell surface staining was observed only on classic
LH/CG targets, granulosa and theca cells of preovulatory
follicles and mature luteal cells, but also in the vaginal
epithelium. This indicates that these cells are prepared for
the selective accumulation of LH/CG signals from the
circulation.
There was also a striking difference in vascular LHR
expression between ovaries and other tissues. In ovarian
(and also striated muscle) vessels the LHR expression was
virtually absent (Fig. 1A, 2A, 3J), while other tissues inves-
tigated, including uterus, brain, skin and vagina, showed
distinct vascular LHR immunoreactivity. We also reported
previously that in the rat the endothelial LHR expression
is absent in testicular vessels, and vessels in other tissues
involved in LH/CG transport into (pituitary) and from the
blood (kidney) [22]. Saturation of LHR in ovarian targets
may be dependent on the precise delivery of small
amounts of circulating LH/CG from the blood into the
extravascular space. A receptor mediated endothelial
transport of hCG has been suggested to represent a model
for general involvement of specific receptors in transport
of other plasma proteins [57,58]. Yet, application of this
theory on our data will indicate that the LH/CG will be
delivered to the uterus, brain, skin and vagina rather than
to the ovary. Hence, the opposite mechanism should be
considered – endothelial LHR expression may suppress
the transport of LH/CG from vessels to the extravascular
space. The LH/CG molecule is smaller than that of albu-
min or IgG, i.e., proteins exhibiting ubiquitous distribu-
tion, so there is no need to enhance rather only prevent
LH/CG transport to inappropriate sites. Binding of LH/
CG to endothelial cells expressing LHR may prevent LH/
CG transport from circulation by electrostatic forces, and
the lack of endothelial LHR expression may be associated
with LH/CG transport mediated by a general mechanism
involved in protein exchange [40].
We report that normal term placentae show virtually no
LHR expression in trophoblastic syncytium while syncy-
tium of some abnormal placentae (immature pheno-
types) exhibits LHR immunoreactivity. This resembles
high LHR expression in first trimester placenta [28], which
is a source of high hCG levels [59]. Yet, hCG levels fall
during the second trimester, and elevated maternal
midtrimester hCG is associated with higher rates of mater-
nal and neonatal complications (pregnancy-induced
hypertension, preeclampsia, gestational diabetes, and
perinatal death) [60–63].
Hence, some abnormal term placentae appear to preserve
syncytium in a younger state, accompanied by high secre-
tion of hCG. In contrast, vascular LHR expression was
detected in sinusoids of chorionic villi from normal term
placentae, but was virtually absent in all abnormal placen-
tae. If the vascular LHR expression represents a barrier for
hCG transport from chorionic villi to the fetal blood (see
above), lack of this barrier may cause high levels of fetal
hCG resulting in perinatal morbidity and mortality [63],
regardless of normal or abnormal hCG production.
Western blot analysis of placental villi and trophoblast
cultures indicates that cultured trophoblast cells show
additional bands, including ~170 kDa species, possibly an
LHR homodimer [19]. Although the ~170 kDa species
persisted in late cultures, other (additional) LHR variants
diminished. This suggests an activation of isolated tro-
phoblast cells and enhanced LHR synthesis with forma-
tion of additional glycosylated LHR variants, particularly
in time 0 and early cultures. When compared to chorionic
villi, trophoblast cultures showed stronger ~59 and 48
kDa species, characteristic for cultured fibroblasts. Indeed,
it has been reported, that differentiation of cultured tro-
phoblast is associated with activation of accompanying
fibroblasts [64].
Early differentiation of granulosa, luteal, and other cell
types expressing LHR was associated with cytoplasmic
LHR immunoreactivity, reflecting receptor synthesis prior
its surface expression. In addition, the CL of pregnancy,
the function of which is highly dependent on CG, also
showed cytoplasmic expression. Hence, it is possible that
high levels of circulating LH/CG, e.g., during pregnancy
and after menopause, may influence not only cells with
surface LH expression, but also cells with cytoplasmic,
and perhaps exclusively nuclear LHR expression (pelvic
floor compartments, including striated muscle). In other
words, cells lacking surface LHR may not be influenced by
temporary increase of LH production during the
preovulatory period of the ovarian cycle due to the "cell
membrane LHR barrier," and the LH effect is probably
also prevented by the "vascular LHR barrier." Yet, high CG
levels during pregnancy may pass the "cell membrane bar-
rier" and act through the cytoplasmic LHR in the CL of
pregnancy and other cells with cytoplasmic expression,
and such effect could be enhanced if the "vascular LHR
barrier" is absent – abnormal placentae of aged pheno-
type and similar putative age-related vascular changes in
other tissues.
But the LH/CG action through the cytoplasmic/perinu-
clear and nuclear LHRs opens a possibility of more direct
LH/CG action within the cells, which may not require a
classic second messenger pathway (cyclic AMP dependent
signaling mechanism) involvement, or this system can act
through the intracellular LHRs. Evidence is accumulating
that a number of other factors modulate the actions of
gonadotropins in the ovary and testis via activation of
alternative signaling pathways and via LHR protein vari-Reproductive Biology and Endocrinology 2003, 1 http://www.RBEj.com/content/1/1/46
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ants, and alternative second messenger pathways for the
transmission of the LHR activation effect exist, which may
not include stimulation of cyclic AMP levels [65–69]. A
question also arises if the nuclear LHR expression in ter-
minally differentiated cells (e.g., striated muscle fibers)
may not indicate a possibility of the direct effect of LH/CG
on modulation of protein synthesis, reflecting certain
effects of sex steroids on their nuclear receptors.
LH/CG causes a relaxation of smooth muscle cells, which
express LHR [36–38] (Fig. 7A). The data presented also
indicate that additional principal cell types in the pelvic
floor show LHR expression, including stromal and fascial
fibroblasts and striated muscle cells. This is associated
with relatively high expression of LHR protein in western
blots, and a fully glycosylated ~92 kDa species in particu-
lar. Interestingly, strong ~59 and 48 kDa proteins
expressed in cultured fibroblasts were not detected in pel-
vic floor lysates, but a distinct ~68 kDa band from mesen-
chymal cells was apparent. We speculate that a ~92 kDa
species in the pelvic floor is a result of interaction of resi-
dent macrophages with pelvic floor fibroblasts.
The hCG secreted by trophoblastic syncytium during preg-
nancy may play an important role in the physiologic
adaptation of the body, and preparation of the pelvic
floor for labor in particular. However, when compared to
hCG, LH has a 10-fold higher LHR binding affinity [20].
Consequently, high LH levels after menopause may cause
pathologic relaxation of the pelvic floor resulting in pelvic
floor disorders.
Strong LHR expression in microglial cells in the brain cor-
tex is of particular interest. Microglial cells are resident
macrophages in the central nervous system, and LHR
expression has been described in other types of human
resident macrophages (ovary, decidua, endometrium and
corpora lutea) [22,33]. Pathological activation of micro-
glia has been reported in a wide range of conditions such
as Alzheimer's disease, cerebral ischemia, prion diseases,
multiple sclerosis, AIDS dementia, and other degenerative
neurological diseases [70,71]. Some of these degenerative
diseases are associated with advanced age and high levels
of circulating LH. High LH levels might pass the presump-
tive LH barrier of brain vessels expressing LHR, or vascular
LHR expression might diminish with age, as in abnormal
term placentae. Yet, elevated maternal mid-trimester cho-
rionic gonadotropin is associated with fetal cerebral
blood flow redistribution and adverse perinatal outcome
[63]. In addition, estrogens, which are known to cause a
diminution of high LH levels in postmenopausal women,
have been reported to be effective in the prevention and
treatment of Alzheimer's disease [72–74]. Microglia
belong among cells of the mononuclear phagocyte system
[75]. Since CG increases secretion of a variety of cytokines
by monocytes, and induces their inflammatory reaction
and phagocytic activity [76–79], high LH levels in aging
individuals may also activate resident macrophages in the
central nervous system and contribute to the development
of Alzheimer's disease and other inflammation-mediated
neurodegenerative diseases.
Outside of the area occupied by microglial cells in the grey
matter of the cerebral cortex, weaker LHR expression was
also detected in some nerve cells. This suggests that such
nerve cells could be directly influenced by LH/CG proteo-
hormones (with unknown consequences), while the
nerve cells among microglial branching processes are pro-
tected from such an effect.
Conclusion
In conclusion, our observations concur with and expand
current knowledge on LHR expression in gonadal and
nongonadal tissues reported by other investigators. We
show that the 3B5 antibody identifies six distinct LHR
protein variants in three different mammalian species.
Subcellular LHR localization varies during cellular differ-
entiation. In contrast to the theory on the role of vascular
hormone receptors in preferential pick up of circulating
hormones, there may be no need to enhance selective pick
up rather only prevent LH/CG transport to inappropriate
sites. Abnormal placental LHR expression may play a role
in the development of abnormal pregnancy and fetal out-
come, and expression of LHR in the pelvic floor compart-
ments suggests that high LH levels in postmenopausal
women may contribute to pelvic floor relaxation and
increased incidence of pelvic floor disorders. High LH lev-
els in aging individuals may also participate in the devel-
opment of inflammation-mediated neurodegenerative
diseases, including Alzheimer's disease.
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